Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer

Cancer Letters

Volumn 268, Issue 1, 2008, Pages 98-109

  Loos, Martin ^a   Giese, Nathalia A ^b   Kleeff, Jörg ^a   Giese, Thomas ^b   Gaida, Matthias M ^b   Bergmann, Frank ^b   Laschinger, Melanie ^a   W Büchler, Markus ^b   Friess, Helmut ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

B7 H1 (PD L1); Costimulation; Interferon ; Pancreatic cancer

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE, TUMOR; CYTOKINES; HUMANS; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 48149092796     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.056     Document Type: Article

References (57)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 58 (2008) 71-96
2. Keleg S., Buchler P., Ludwig R., Buchler M.W., and Friess H. Invasion and metastasis in pancreatic cancer. Mol. Cancer 2 (2003) 14
3. Kleeff J., Michalski C., Friess H., and Buchler M.W. Pancreatic cancer: from bench to 5-year survival. Pancreas 33 (2006) 111-118
4. Sener S.F., Fremgen A., Menck H.R., and Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 189 (1999) 1-7
5. Kleeff J., Michalski C.W., Friess H., and Buchler M.W. Surgical treatment of pancreatic cancer: the role of adjuvant and multimodal therapies. Eur. J. Surg. Oncol. (2007)
6. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., and Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350 (2004) 1200-1210
7. Carreno B.M., Carter L.L., and Collins M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr. Opin. Pharmacol. 5 (2005) 424-430
8. Warshaw A.L., and Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326 (1992) 455-465
9. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., Lennon V.A., Celis E., and Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002) 793-800
10. Gajewski T.F., Meng Y., and Harlin H. Immune suppression in the tumor microenvironment. J. Immunother. (1997) 29 (2006) 233-240
11. Laheru D., and Jaffee E.M. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 5 (2005) 459-467
12. von Bernstorff W., Voss M., Freichel S., Schmid A., Vogel I., Johnk C., Henne-Bruns D., Kremer B., and Kalthoff H. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 7 (2001) 925s-932s
13. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2 (2002) 116-126
14. Oosterwegel M.A., Greenwald R.J., Mandelbrot D.A., Lorsbach R.B., and Sharpe A.H. CTLA-4 and T cell activation. Curr. Opin. Immunol. 11 (1999) 294-300
15. Krummel M.F., and Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183 (1996) 2533-2540
16. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
17. Egen J.G., Kuhns M.S., and Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3 (2002) 611-618
18. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
19. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., Duray P.H., Steinberg S.M., Allison J.P., Davis T.A., and Rosenberg S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100 (2003) 8372-8377
20. Loser K., Scherer A., Krummen M.B., Varga G., Higuchi T., Schwarz T., Sharpe A.H., Grabbe S., Bluestone J.A., and Beissert S. An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice. J. Immunol. 174 (2005) 5298-5305
21. Maker A.V., Phan G.Q., Attia P., Yang J.C., Sherry R.M., Topalian S.L., Kammula U.S., Royal R.E., Haworth L.R., Levy C., Kleiner D., Mavroukakis S.A., Yellin M., and Rosenberg S.A. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12 (2005) 1005-1016
22. Small E.J., Tchekmedyian N.S., Rini B.I., Fong L., Lowy I., and Allison J.P. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13 (2007) 1810-1815
23. Dong H., Zhu G., Tamada K., and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5 (1999) 1365-1369
24. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., Chapoval A.I., Flies D.B., Bajorath J., and Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18 (2003) 849-861
25. Ishida Y., Agata Y., Shibahara K., and Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11 (1992) 3887-3895
26. Nishimura H., and Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 22 (2001) 265-268
27. Dong H., and Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 81 (2003) 281-287
28. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A., Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A.H., and Freeman G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001) 261-268
29. Ghebeh H., Mohammed S., Al-Omair A., Qattan A., Lehe C., Al-Qudaihi G., Elkum N., Alshabanah M., Bin Amer S., Tulbah A., Ajarim D., Al-Tweigeri T., and Dermime S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (2006) 190-198
30. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., and Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10 (2004) 5094-5100
31. Nakazawa A., Dotan I., Brimnes J., Allez M., Shao L., Tsushima F., Azuma M., and Mayer L. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 126 (2004) 1347-1357
32. Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M., and Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13 (2007) 2151-2157
33. Ohigashi Y., Sho M., Yamada Y., Tsurui Y., Hamada K., Ikeda N., Mizuno T., Yoriki R., Kashizuka H., Yane K., Tsushima F., Otsuki N., Yagita H., Azuma M., and Nakajima Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11 (2005) 2947-2953
34. Thompson R.H., Kuntz S.M., Leibovich B.C., Dong H., Lohse C.M., Webster W.S., Sengupta S., Frank I., Parker A.S., Zincke H., Blute M.L., Sebo T.J., Cheville J.C., and Kwon E.D. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66 (2006) 3381-3385
35. Thompson R.H., Gillett M.D., Cheville J.C., Lohse C.M., Dong H., Webster W.S., Krejci K.G., Lobo J.R., Sengupta S., Chen L., Zincke H., Blute M.L., Strome S.E., Leibovich B.C., and Kwon E.D. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. USA 101 (2004) 17174-17179
36. Wu C., Zhu Y., Jiang J., Zhao J., Zhang X.G., and Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 108 (2006) 19-24
37. Xiao J.X., Bai P.S., Lai B.C., Li L., Zhu J., and Wang Y.L. B7 molecule mRNA expression in colorectal carcinoma. World J. Gastroenterol. 11 (2005) 5655-5658
38. Liu X., Gao J.X., Wen J., Yin L., Li O., Zuo T., Gajewski T.F., Fu Y.X., Zheng P., and Liu Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med. 197 (2003) 1721-1730
39. Pardoll D. Does the immune system see tumors as foreign or self. Ann. Rev. Immunol. 21 (2003) 807-839
40. Thornton A.M., and Shevach E.M. CD4+CD25+immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188 (1998) 287-296
41. Hiraoka N., Onozato K., Kosuge T., and Hirohashi S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12 (2006) 5423-5434
42. Erkan M., Kleeff J., Esposito I., Giese T., Ketterer K., Buchler M.W., Giese N.A., and Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24 (2005) 4421-4432
43. Cordon-Cardo C., Fuks Z., Drobnjak M., Moreno C., Eisenbach L., and Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 51 (1991) 6372-6380
44. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mule J.J., Rosenberg S.A., and Bennink J.R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177 (1993) 265-272
45. Ebrahimi B., Tucker S.L., Li D., Abbruzzese J.L., and Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101 (2004) 2727-2736
46. Blank C., Kuball J., Voelkl S., Wiendl H., Becker B., Walter B., Majdic O., Gajewski T.F., Theobald M., Andreesen R., and Mackensen A. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119 (2006) 317-327
47. Flies D.B., and Chen L. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. (1997) 30 (2007) 251-260
48. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C., David O., Burow M., Gordon A., Dhurandhar N., Myers L., Berggren R., Hemminki A., Alvarez R.D., Emilie D., Curiel D.T., Chen L., and Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9 (2003) 562-567
49. Bellone G., Turletti A., Artusio E., Mareschi K., Carbone A., Tibaudi D., Robecchi A., Emanuelli G., and Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 155 (1999) 537-547
50. Lee S.J., Jang B.C., Lee S.W., Yang Y.I., Suh S.I., Park Y.M., Oh S., Shin J.G., Yao S., Chen L., and Choi I.H. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 580 (2006) 755-762
51. Kalvakolanu D.V., and Borden E.C. An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest. 14 (1996) 25-53
52. Chang C.J., Chen Y.H., Huang K.W., Cheng H.W., Chan S.F., Tai K.F., and Hwang L.H. Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 45 (2007) 746-754
53. Bui J.D., Carayannopoulos L.N., Lanier L.L., Yokoyama W.M., and Schreiber R.D. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 176 (2006) 905-913
54. Antonia S.J., Munoz-Antonia T., Soldevila G., Miller J., and Flavell R.A. B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Res. 55 (1995) 2253-2256
55. Tamura H., Dan K., Tamada K., Nakamura K., Shioi Y., Hyodo H., Wang S.D., Dong H., Chen L., and Ogata K. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin. Cancer Res. 11 (2005) 5708-5717
56. Nishikawa H., Kato T., Tawara I., Takemitsu T., Saito K., Wang L., Ikarashi Y., Wakasugi H., Nakayama T., Taniguchi M., Kuribayashi K., Old L.J., and Shiku H. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102 (2005) 9253-9257
57. Ghebeh H., Barhoush E., Tulbah A., Elkum N., AlTeigeri T., and Dermime S. FOXP3+Tregs and B7-H1+/PD1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implications for immunotherapy. BMC Cancer 23 (2008) 57